Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies

Sirtuins (SIRTs) are NAD+-dependent histone deacetylases, which play a key role in cancer progression; however, their prognostic values in breast cancer (BC) remain a subject of debate and controversy. Accumulative evidence suggests that each sirtuin possesses individual character, implicating its r...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Anna Wawruszak, Jarogniew Luszczki, Damian Bartuzi, Joanna Kalafut, Estera Okon, Arkadiusz Czerwonka, Andrzej Stepulak
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis Group 2025-12-01
Serie:Journal of Enzyme Inhibition and Medicinal Chemistry
Soggetti:
Breast cancer
paclitaxel
selisistat
sirtuin inhibitor
histone deacetylase inhibitor
Accesso online:https://www.tandfonline.com/doi/10.1080/14756366.2025.2458554
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi